Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy

Ergül, Nurhan; Kadıoğlu, Hüseyin; Yıldız, Şeyma; Yücel, Serap; Güçin, Zühal; Erdoğan, Ergun; Aydın, Mehmet; Müslümanoğlu, Mahmut

doi:10.1177/0284185114539786

Cited by 38 publications

(80 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evidence level II, strong recommendation. [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28] For more information, see Tables 3-5. 3a. 18F-FDG PET/CT should be used in high-risk patients, such as those with inflammatory BC.…”

Section: Resultsmentioning

confidence: 99%

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

et al. 2017

View full text Add to dashboard Cite

Current guidelines do not systematically recommend 18F-FDG PET/CT for breast cancer staging; and the recommendations and level of evidence supporting its use in different groups of patients vary among guidelines. This review summarizes the evidence about the role of 18F-FDG PET/CT in breast cancer staging and the therapeutic and prognostic impact accumulated in the last decade. Other related aspects, such as the association of metabolic information with biology and prognosis are considered and evidence-based recommendations for the use of 18F-FDG PET/CT in breast cancer staging are offered. We systematically searched MEDLINE for articles reporting studies with at least 30 patients related to clinical questions following the Problem/Population, Intervention, Comparison, and Outcome framework. We critically reviewed the selected articles and elaborated evidence tables structuring the summarized information into methodology, results, and limitations. The level of evidence and the grades of recommendation for the use of 18F-FDG PET/CT in different contexts are summarized. Level III evidence supports the use of 18F-FDG PET/CT for initial staging in patients with recently diagnosed breast cancer; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a weak recommendation in this population. In patients with locally advanced breast cancer, level II evidence supports the use of 18F-FDG PET/CT for initial staging; the diagnostic and therapeutic impact of the 18F-FDG PET/CT findings is sufficient for a strong recommendation in this population. In patients with recently diagnosed breast cancer, the metabolic information from baseline 18F-FDG PET/CT is associated with tumor biology and has prognostic implications, supported by level II evidence. In conclusion, 18F-FDG PET/CT is not recommended for staging all patients with early breast cancer, although evidence of improved regional and systemic staging supports its use in locally advanced breast cancer. Baseline tumor glycolytic activity is associated with tumor biology and prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Recently, to evaluate their diagnostic ability in this area, other techniques have been tested, such as positron emission sonography, positron emission sonography/computed tomography, and magnetic resonance imaging . However, a newer sonographic modality has been available for some time now: contrast‐enhanced sonography.…”

mentioning

confidence: 99%

Role of Contrast‐Enhanced Sonography in the Evaluation of Axillary Lymph Nodes in Breast Carcinoma: A Monocentric Study

Agliata

Valeri

Argalia

et al. 2017

J of Ultrasound Medicine

View full text Add to dashboard Cite

show abstract

“…MR imaging has been shown to be more sensitive but less specific than PET/CT 37,38,42 or PET alone for multifocality, 43 whereas PET/CT has generally been shown to have a higher sensitivity for axillary nodal metastases. 38,42,43 PET and MR imaging have demonstrated similar performance for the detection of internal mammary adenopathy. 44 MR imaging and PET/MR imaging have been shown to be more likely than PET/CT to determine the correct maximum diameter of the tumor (T stage), which may be useful in surgical and oncologic planning.…”

Section: Mr Imaging and Pet In Localized Breast Examinationsmentioning

confidence: 99%

Breast PET/MR Imaging

Melsaether

Moy

2017

Radiologic Clinics of North America

View full text Add to dashboard Cite

Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy

Cited by 38 publications

References 19 publications

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging

Role of Contrast‐Enhanced Sonography in the Evaluation of Axillary Lymph Nodes in Breast Carcinoma: A Monocentric Study

Breast PET/MR Imaging

Contact Info

Product

Resources

About